Introduction {#Sec1}
============

Men with lower urinary tract symptoms due to benign prostatic hyperplasia (LUTS-BPH) suffer to various degrees and severity of storage, voiding, and post-micturition symptoms \[[@CR1]\]. Although voiding symptoms are more frequent, storage symptoms are more bothersome \[[@CR1]--[@CR3]\]. Storage symptoms comprise urgency, frequency, nocturia, and urgency urinary incontinence and are congruent with OAB \[[@CR4]\]. Traditionally, BPH or related conditions were blamed for all LUTS in adult men; however, recent analyses demonstrated that \>50% of men with LUTS--BPH have no signs of BOO of which \>50% have OAB and urodynamically confirmed detrusor overactivity \[[@CR5]\]. These men are often treated insufficiently with α-blockers alone \[[@CR6]\]. Although treatment of storage symptoms/OAB with antimuscarinics is effective in both genders, physicians are still reluctant to prescribe antimuscarinics in adult men due to the theoretical threat of increasing PVR or urinary retention.

Several randomized-controlled trials or cohort studies with antimuscarinics as monotherapy (MT) \[[@CR7]--[@CR11]\] or together with α-blockers in combination therapy (CT) \[[@CR12]--[@CR18]\] in men have demonstrated that OAB symptoms and IPSS can be effectively reduced with antimuscarinics. The possible role of CT was mostly tested as add-on of the antimuscarinic to existing but insufficiently effective α-blocker therapy, which makes it difficult to judge whether it indicated a benefit of CT or only demonstrated the efficacy of an antimuscarinic in α-blocker non-responders. A pivotal study has applied the inclusion criteria of both classical LUTS--BPH and OAB studies and compared the effects of tamsulosin, tolterodine, and their combination with those of placebo \[[@CR9]\]. With such inclusion criteria, either MT was only modestly effective when compared to placebo, whereas CT was effective against a range of symptoms.

Only one non-interventional study (NIS) has been published investigating tolterodine under real-life conditions in men with OAB and Q~max~ ≥15 ml/s, thereby assuming non-obstructed BPH \[[@CR19], [@CR20]\]. However, no real-life data are yet available for other antimuscarinics or adult men with decreased baseline Q~max~. We, therefore, conducted a NIS in adult men with normal or reduced Q~max~ using propiverine, a muscarinic receptor antagonist with additional calcium influx inhibitor \[[@CR21]\] and α~1~-adrenoceptor blocking properties \[[@CR22]\]. The aim of this trial was to evaluate in adult men with OAB whether (1) efficacy depends on baseline Q~max~, (2) reduction in OAB symptoms with propiverine ER 30 mg alone (MT) is as effective as with CT using propiverine ER 30 mg together with α-blockers, (3) reduction in overall symptoms, as measured by IPSS, is as effective with MT as with CT, and (4) treatment with propiverine ER 30 mg is safe with regard to PVR and urinary retention.

Patients and methods {#Sec2}
====================

Study design {#Sec3}
------------

Between May 2008 and January 2009, 557 office-based urologists in Germany participated in this prospective NIS that consisted of three visits. At visit 1, the following parameters were recorded: demographic data, patient history (including previous or current diseases and medication), urinanalysis, 24-h bladder diary (urgency episodes, voiding frequency, nocturia, and incontinence episodes), IPSS (sum of answers to questions 1--7), Q~max~ and voided volume during free uroflowmetry, and ultrasonic PVR as well as prostate volume measurements. At visits 2 and 3, after four and 12 weeks of treatment with propiverine ER, the variables of the bladder diary, IPSS, and PVR were recorded again. Additionally, patient-reported adverse events were documented. In Germany, approval for NIS by an ethic committee was not mandatory at this time.

Inclusion and exclusion criteria {#Sec4}
--------------------------------

Men aged ≥40 years with OAB symptoms (urgency with or without urgency incontinence, frequency \>8/24 h, nocturia ≥2/night) were treated with propiverine ER 30 mg o.d. alone (MT) or as add-on to existing treatment with α-blockers (CT) if they met the following inclusion criteria: Q~max:~ ≥10 ml/s at voided volume ≥100 ml, PVR \<100 ml, prostate volume \<40 ml, and IPSS \<20. Exclusion criteria were the following: current or recurrent urinary tract infection, stress incontinence, catheterization, neurological history or neurogenic bladder dysfunction, history of lower urinary tract surgery within the last 6 months, use of 5α-reductase inhibitors, bladder or prostate cancer, or interstitial cystitis/painful bladder syndrome.

Efficacy and safety analyses {#Sec5}
----------------------------

OAB symptoms and IPSS were analyzed using the intent-to-treat (ITT) population, defined as patients who met inclusion and exclusion criteria, received at least one dose of propiverine ER 30 mg, and had at least two visits. The ITT population was post hoc stratified by Q~max~ (≥15 ml/s vs. \<15 ml/s) and the use of MT vs. CT. All adverse events were monitored throughout the observational period (baseline to week 4 or 12). Patients who took at least one dose of propiverine were included in the safety analysis.

Statistical analysis {#Sec6}
--------------------

For descriptive statistics, we report means with 95% confidence intervals. Significance of baseline-end data were calculated with the two-sided paired t-tests and intergroup analysis by independent samples t-test. A significance level of 5% was applied for all statistical tests. Statistical analysis was performed with SAS^®^ software (Cary, NC, USA).

Results {#Sec7}
=======

Study population {#Sec8}
----------------

A total of 2,219 men participated in the study and were involved in safety analysis, of which 1,849 men (83.3%) were included in the efficacy analysis. Baseline demographic and clinical data of the ITT population are shown in Table [1](#Tab1){ref-type="table"}. Arterial hypertension (21.7%) and diabetes mellitus (12.2%) were the most common concomitant diseases and responsible for the majority of co-medications used prior to the study.Table 1Baseline and clinical data of all patients of the ITT population and comparison between group A (Q~max~ ≥15 ml/s) and group B (Q~max~ \<15 ml/s); values given as means and 95% confidence intervals (95% CI)ParameterAll participants\
(*n* = 1,849)Group A\
(*n* = 770)Group B\
(*n* = 1,079)*P*-value\
(Group A vs. B)Mean age (years)66.0 (65.6--66.5)64.3 (63.6--65.0)67.3 (66.7--67.8)**\<0.001**IPSS16.9 (16.4--17.2)16.6 (16.2--16.9)17.2 (16.7--17.6)0.706Prostate volume (ml)37.2 (36.6--37.7)34.9 (34.1--35.8)38.7 (38.0--39.4)**\<0.001**Q~max~ (ml/s)^†^14.8 (14.5--15.1)19.4 (18.8--20.0)11.5 (11.4--11.6)Not applicableVoided volume (ml)^†^209 (206--212)223 (218--229)199 (195--203)**\<0.001**Post-void residual urine (ml)36 (34--37)28 (26--30)41 (39--43)**\<0.001**Urgency episodes/24 h (*n*)9.4 (9.1--9.6)9.7 (9.3--10.2)9.1 (8.8--9.4)0.099Incontinence episodes/24 h (*n*)2.0 (1.9--2.2)1.9 (1.7--2.1)2.1 (2.0--2.3)**0.001**Voiding frequency/24 h (*n*)13.5 (13.3--13.7)13.4 (13.1--13.6)13.6 (13.3--13.8)**0.025**Nocturia (*n*)3.5 (3.5--3.6)3.4 (3.3--3.5)3.7 (3.5--3.8)**0.005***Q*~max~ Maximum urinary flow rate,*IPSS* International Prostate Symptom Score^†^Obtained by free uroflowmetrySignificant values are indicated in bold

At study entry, 770 men (41.6%) had Q~max~ ≥15 ml/s (group A) and 1,079 men (58.4%) had Q~max~ \<15 ml/s (group B). In group A, 291 (37.8%) and 479 men (62.2%) received MT and CT, respectively. In group B, 184 men (17.1%) had MT and 895 CT (82.9%). Tamsulosin was the most commonly used α-blocker (79.9%), followed by alfuzosin (13.2%). Patients in group B were significantly older, had greater prostate volumes and PVR, more incontinence episodes, higher voiding frequencies and nocturia, and lower voided volumes (Table [1](#Tab1){ref-type="table"}). IPSS and urgency episodes were comparable between the group A and B.

Efficacy analysis {#Sec9}
-----------------

### Diary variables {#Sec10}

Significant improvements from baseline to study end were demonstrated for all variables of the bladder diary. For the overall ITT population, the number of 24-h urgency episodes declined from 9.4 to 2.8 (mean change −6.4/−68%), 24-h incontinence episodes from 2.0 to 0.3 (mean change −1.7/−85%), 24-h voiding frequency from 13.5 to 8.1 (mean change −5.4/−40%), and nocturia from 3.5 to 1.5 (mean change −2.1/−60%). The proportion of incontinent men decreased from 58.2% at beginning of the study to 15.3% at study end. There were no statistical differences between the outcomes of group A and B as well as between MT and CT (Table [2](#Tab2){ref-type="table"}).Table 2Treatment results of bladder diary variablesUrgency episodes/24 hIncontinence episodes/24 hVoiding frequency/24 hNocturiaPropiverine ERPropiverine ER + α-BlockerPropiverine ERPropiverine ER + α-BlockerPropiverine ERPropiverine ER + α-BlockerPropiverine ERPropiverine ER + α-Blocker*Group A*Baseline10.0 (9.3--10.8)9.6 (9.0--10.1)1.9 (1.6--2.3)1.9 (1.6--2.2)13.1 (12.6 --3.5)13.5 (13.2--13.9)3.4 (3.2--3.6)3.4 (3.3--3.5)End of Observation3.5 (4.6--5.7)2.7 (2.4--3.0)0.3 (0.2--0.4)0.3 (0.2--0.4)7.8 (7.5--8.0)8.0 (7.8--8.2)1.3 (1.2--1.4)1.4 (1.3--1.5)Difference−6.7\* (−7.4 to −6.0)−6.7 (−7.2 to −6.2)−1.5\* (−1.9 to −1.2)−1.6\* (−1.9 to −1.4)−5.4\* (−5.9 to −5.0)−5.6\* (−5.9 to −5.2)−2.1\* (−2.3 to −1.9)−2.0\* (−2.2 to −1.9)Change (%)−67.0\*−69.8\*−78.9\*−84.2\*−42.0\*−41.5\*−61.8\*−58.8\**P*-value0.9230.6310.6850.349*Group B*Baseline9.5 (8.7 to 9.4)9.0 (8.7 to 9.4)2.0 (1.6 to 2.4)2.2 (2.0 to 2.3)13.3 (12.9 to 13.7)13.6 (13.4 to 13.9)3.5 (3.3 to 3.7)3.7 (3.5 to 3.8)End of Observation3.0 (2.5 to 3.5)2.7 (2.4 to 2.9)0.4 (0.2 to 0.5)0.3 (0.3 to 0.4)8.2 (7.8 to 8.5)8.2 (8.0 to 8.4)1.5 (1.3 to 1.6)1.5 (1.4 to 1.6)Difference−6.4\* (−7.1 to −5.7)−6.3\* (−6.6 to −6.0)−1.6\* (−2.0 to −1.3)−1.8\* (−2.0 to −1.6)−5.2\* (−5.6 to −4.9)05.4\* (−5.6 to −5.2)−2.1\* (−2.2 to −1.9)−2.2\* (−2.3 to −2.0)Change (%)−67.4\*−70.0\*−80.0\*−81.8\*−39.1\*−39.7\*−60.0\*−59.5\**P*-value0.8310.4840.4790.476*Comparison Group A versus Group BP*-value0.5890.1430.6870.3910.4630.4560.6170.137Values presented as means and 95% confidence intervals (95% CI)Group A = patients with Q~max~ ≥15 ml/s; group B = patients with Q~max~ \<15 ml/s\* *P* \< 0.001 (difference between baseline and end of observation)

### IPSS {#Sec11}

Total IPSS decreased significantly from beginning of the study to week 12 in all four patient groups. While men in group A exhibited similar efficacy with MT (−4.6) and CT (−5.1), patients in group B with MT reported a significantly smaller IPSS improvement than with CT (−3.7 vs. −5.3; Fig. [1](#Fig1){ref-type="fig"}).Fig. 1Mean absolute IPSS changes from baseline to end of observation in group A (*gray lines*) and group B (*black lines*), \*significant against baseline (*P* \< 0.001),^†^significant difference between treatment week 4 and 12 (*P* \< 0.001)

### Uroflowmetry {#Sec12}

No significant change in Q~max~ was observed within group A (0 ml/s with MT vs. + 0.2 ml/s with CT; *P* = 0.768) or group B (+2.7 ml/s with MT vs. +3.4 ml with CT; *P* = 0.063). However, Q~max~ was significantly different between the treatment regimes when group A was compared with group B (*P* \< 0.001).

In group A, mean voided volumes increased by 40 and 46 ml with MT and CT, respectively (*P* = 0.301). In group B, mean voided volume increased by 35 and 52 ml with MT and CT, respectively, but the increase was significantly higher for CT (*P* \< 0.001).

Safety and tolerability analysis {#Sec13}
--------------------------------

### Post-void residual volume or urinary retention {#Sec14}

Mean PVR change was not clinically relevant during the treatment period. At week 12, mean PVR decreased to 22 ml in group A (−6 ml) and 27 ml in group B (−15 ml). Despite the overall reduction in mean PVR, 412 patients (18.6%) of the safety population had PVR increase (mean +19 ml, range 5--250 ml) including 154 men (6.9%) with PVR increase of ≥20 ml (mean increase +35 ml, mean PVR: 57 ml) but only two men experienced acute urinary retention requiring catheterization (one with CT and baseline Q~max~ 15.0 ml/s; the other with MT and baseline Q~max~ 9.0 ml/s).

### Treatment discontinuation and adverse events {#Sec15}

Two thousand and seventy patients (93.3%) completed the study. Sixty men (2.7%) were lost to follow-up and 89 (4%) discontinued the study. The reasons for premature treatment termination were insufficient efficacy (1.1%), adverse events (0.9%), or patient desire (0.8%). Ten men (0.5%) with increased PVR (mean baseline PVR 50 ml and increase to 125 ml during the first 4 weeks) and two men (0.1%) with urinary retention also discontinued the treatment.

Adverse drug reactions were reported by 108 patients (4.9%) of which xerostomia (3.6%), constipation (0.9%), dizziness (0.3%), and accommodation disorder (0.3%) occurred most frequently.

Discussion {#Sec16}
==========

Although it often remains unclear in clinical practice whether male LUTS are caused by BPH and/or OAB, convincing evidence has accumulated that men can benefit from antimuscarinics, particularly when storage symptoms dominate and/or insufficient treatment response has been obtained by prior α-blocker treatment. Key questions for clinical practice are who benefits from an antimuscarinic, who from α-blocker, and who from CT? The presence of BOO may be one criterion to make this choice, particularly because it remains unclear whether the fear of urinary retention by exposing men with enlarged prostates to antimuscarinics is warranted. Therefore, we have explored in a real-life setting whether efficacy of propiverine differs between men with ≥15 ml/s and \<15 ml/s and how this is affected by MT and CT.

Critique of methods {#Sec17}
-------------------

NIS and randomized-controlled trials have distinct advantages and disadvantages. While controlled trials have high internal validity due to randomization, blinding, and, in most cases, source data monitoring, they have limited external validity because they typically recruit somewhat artificial populations due to their strict inclusion and exclusion criteria. In contrast, NIS have limited internal validity due to their lack of a control group but have a greater external validity because they have less rigorous inclusion and exclusion criteria and, hence, are more representative for patients receiving treatment in real practice. Therefore, NIS cannot substitute for controlled trials but rather provide complementary evidence. A NIS cannot provide information on the absolute efficacy or safety of a drug and such data have already been reported for propiverine from randomized-controlled trials \[[@CR23]\].

Q~max~ assessment does not substitute for a vigorous BOO evaluation by pressure-flow studies but remains the main approach in routine practice. While Q~max~ ≥15 ml/s reflects an absence of BOO in 97% of patients, men with Q~max~ \<10 ml/s have bladder dysfunction due to different causes, e.g. detrusor underactivity or, in 69%, BOO \[[@CR24]\]. Q~max~ 10--14.9 ml/s is more difficult to interpret as it may or may not indicate BOO. For safety reasons and in line with the summary of product characteristics of propiverine, we defined Q~max~ \<10 ml/s as well as limits for PVR and prostate volume as exclusion criteria in our study. Therefore, our patient stratification primarily compared men with ≥15 versus those with 10--14.9 ml/s as a necessary compromise between scientific desirability and practical feasibility in a NIS, generating a comparison of men unlikely to have BOO versus those at risk of BOO.

Baseline data {#Sec18}
-------------

Baseline data of the present study are very similar to those found in NIS with other antimuscarinics performed in Germany \[[@CR19], [@CR25]--[@CR27]\], indicating that our patients are representative for those typically seen by German urologists.

Given that Q~max~ decreases and prostate size, IPPS, and incontinence episodes increase with age, it is not surprising that our two main groups of patients defined by their Q~max~ differed somewhat by age, prostate size, or incontinence episode frequency. However, these differences were surprisingly small. Therefore, we chose to present direct group comparisons for treatment effects rather than applying multiple regression models with one or more of those variables as additional explanatory variables.

Treatment effects {#Sec19}
-----------------

The overall efficacy of propiverine ER in the present NIS in men was similar to efficacy reported with propiverine immediate release in a mixed gender population under controlled conditions. The key finding of our study is that propiverine improved storage symptoms similarly in men with Q~max~ ≥15 or 10--14.9 ml/s and MT or add-on to existing α-blocker treatment. The group with lower Q~max~ may comprise men with low-grade BOO and/or with detrusor underactivity \[[@CR24]\]. On mechanistic grounds, low-grade BOO is unlikely to affect OAB improvement by antimuscarinics. Detrusor underactivity could impair efficacy of an antimuscarinic in a smooth muscle-centric view but recent evidence suggests that antimuscarinics act in part via the urothelium and/or afferent nerves \[[@CR28]\]. While the present data are unsuitable to prove that point, they certainly are in line with this view.

Perhaps even more interesting is the similar efficacy of propiverine against OAB symptoms when used as MT or add-on to α-blocker treatment. In men with LUTS-BPH, α-blockers are effective against storage symptoms at group level \[[@CR3]\]. The fact that propiverine patients in the CT group received antimuscarinics as add-on indicates that this group may represent relative non-responders to α-blockers, a situation where efficacy of an antimuscarinic is likely. Noteworthy, the only relevant exception from the similar efficacy of propiverine in MT and CT is the small, but still significant improvement of IPSS in CT of men with Q~max~ \<15 ml/s. At present, we have no good explanation for this finding but it is in line with studies demonstrating that CT is superior to both antimuscarinic and α-blocker MT in reducing IPSS \[[@CR9]\].

The overall tolerability in our study was very good, and adverse drug reactions were reported less frequently than in randomized-controlled trials with propiverine \[[@CR23]\]. This situation is typical for NIS and has also been observed with other antimuscarinics \[[@CR19], [@CR25]--[@CR27]\]. A key safety consideration in the use of antimuscarinics in elderly men is the possible risk of inducing increased PVR/urinary retention. A meta-analysis showed an incidence of urinary retention while antimuscarinic treatment in men of 0.8% \[[@CR29]\]. In line with previous controlled studies with propiverine \[[@CR12], [@CR13], [@CR18]\], the observed changes in PVR were small and acute urinary retention occurred only rarely in the present study. This may at least in part be attributable to study design that excluded men with the largest risk, i.e. those with BOO and risk factors, such as existing large PVR or prostates for safety reasons and in line with the drug label. Moreover, it is a general impression that retention occurs less frequently when antimuscarinics are used as add-on to existing α-blocker treatment, probably because α-blockers per se reduce the risk of retention in studies up to one year \[[@CR30]\]. In this regard, the recently demonstrated α~1~-adrenoceptor antagonist properties of propiverine \[[@CR22]\] may also have contributed to the low observed incidence of retention.

Conclusions {#Sec20}
===========

Under real-life conditions, the efficacy of propiverine against storage symptoms is similar in men with Q~max~ 10--14.9 and ≥15 ml/s and independent of the use of MT or add-one use to existing α-blocker treatment. However, overall IPSS improvement, at least in some groups of men, may be better with CT than propiverine MT. When certain safety considerations are followed (Q~max~ ≥10 ml/s), propiverine ER with or without concomitant α-blockers causes only small if any PVR increases and has a very low risk of urinary retention.
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